EDITORIAL

Enthusiasm Tempered by Caution

What experience has taught us about protease inhibitors, protease resistance, and protease sequencing
PAUL A. VOLBERDING, M.D.

---

CLINICAL CARE

The Problem of Protease Resistance

Because resistance will develop over time to all of the protease inhibitors, clinicians should think in terms of successive regimens
STEVEN G. DEEKS, M.D., AND JAMES O. KAHN, M.D.

---

NEWSLINE

Newsline ... Newsline ... Newsline ...

The clinical significance of surrogate markers: CD4 counts and HIV RNA levels do predict rate of disease progression ... In treating MAC, less may be more: Adding clofazimine to clarithromycin and ethambutol does not improve symptoms or survival ... Is resistance always a bad thing? Repeated mutation may eventually render HIV ineffective ... Enhancing saquinavir levels with ritonavir: Two-drug combination overcomes chief limitation of saquinavir, its low bioavailability ... Clinton Administration proposes extending Medicaid benefits to people with asymptomatic HIV: Policy change will make protease inhibitors available to thousands who have not yet developed AIDS ... A novel NNRTI with activity against resistant strains: Another entrant in a rapidly expanding field ... New macrolide inhibits late-stage HIV replication: First compound in its class shows strong in vitro antiretroviral activity ... Approval sought for new formulation of saquinavir ...

---

PULL OUT AND SAVE

Strategies to Establish and Maintain Optimal Adherence

Steps that can be taken by healthcare professionals, working in partnership with their patients, to increase compliance with multidrug antiretroviral regimens

---

CONTINUING CARE

Compliance: How You Can Help

With the advent of multidrug regimens, adherence to therapy is more than a challenge, it is a necessity
MARGARET A. CHESNEY, PH.D.

---

THERAPEUTIC ADVANCES

The Next Generation of Antiretroviral Agents

Potent and promising new drugs will soon be available to combat HIV infection
HAROLD A. KESSLER, M.D.